Publication
Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma.
Mahipal Sinnollareddy, Kinjal Sanghavi, Leonid Gibiansky, Tommy Li, Matthew Putnins, Mohamed-Eslam F Mohamed, Poliana Patah, Elena Favaro, Manish Gupta, Apurvasena Parikh, Steven Xu
- Source
- PubMed
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260910-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Epcoritamab is approved for treating various relapsed/refractory (R/R) lymphomas. In a phase I/II study in R/R follicular lymphoma (FL) patients, epcoritamab demonstrated high response rates (EPCORE NHL-1: objective response rate [ORR]: 82.0%, complete response [CR] rate: 62.5% [N =…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 2
- trialNCT03625037registry_reference1.00
- trialNCT04542824registry_reference1.00
Registered trialsNCT03625037NCT04542824
Curated evidence
Evidence citing this paper (0)
Data not yet available